Progetto BIPCOM

Medical comorbidities in bipolar disorder: clinical validation of risk factors and biomarkers to improve prevention and treatment

Lombady partner:

- Giovanni De Girolamo, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli

 Pathology of interest:

  Bipolar Diversity

 Area of research:

  Psychiatry

 Start date:

  01 February 2023

 End date:

  31 January 2026

 Funding:

  € 497.680,00

 Project partners:
  • IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Unit of Epidemiological Psychiatry, Italy
  • University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
  • University Hospital Frankfurt, Germany
  • School of Medical Sciences, Örebro University, Sweden
  • Centre of Excellence NORMENT and University of Oslo, Norway
  • University of Paris Est (UPEC) and Hôpitaux Universitaires Mondor, Assistance-Publique-Hôpitaux de Paris, France
  • Institut de Recerca-Hospital de la Santa Creu I Sant Pau and Universitat Autònoma de Barcelona, Spain
  • Deutsche Gesellschaft Für Bipolare Störungen (Gsbd) E.V., Germany

Bipolar Disorder (BD) is a common, heritable, chronic, and recurrent disorder that represents a critical public health problem, due to its prevalence, its high degree of disability and psychiatric and medical comorbidities (MC). The project on “Medical comorbities in bipolar disorder: clinical validation of risk factors and biomarkers to improve prevention and treatment” (BIPCOM) aims to study MC in people with BD targeting 2 main objectives: (1) to identify prevalence rates, risk and protective factors and natural history of MC among subjects with BD, through analyses of the Nordic medical registers and a cross-sectional study exploiting existing datasets of patients with BD; (2) to conduct a clinical study involving 400 subjects to assess the overall clinical profile of these patients and study the onset of medical comorbidities. BIPCOM will be implemented through continuous consultations with stakeholders (scientific and patients’ associations, users, and families), for ensuring results’ acceptability and transferability.